RxDoctor Payments Data

Julius Gorospe, MD

Family Medicine · Jacksonville, FLNPI 1215999842

Payments from drug & device makers

$10,814in general payments, 2019–2025

Across 586 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$809
  • Lilly USA, LLC$793
  • Abbott$714
  • AstraZeneca$707
  • Amgen$684
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$10,785100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,814 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$233,261
Medicare patients
346
Services billed
5,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$65,783
JardianceEmpagliflozin38$59,121
EliquisApixaban43$54,213
OzempicSemaglutide33$43,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,112
TrulicityDulaglutide16$18,771
VraylarCariprazine Hcl12$17,454
RexultiBrexpiprazole12$16,512
MyrbetriqMirabegron14$15,829
LinzessLinaclotide19$12,358
GemtesaVibegron13$10,887
SymbicortBudesonide/Formoterol Fumarate22$10,400
Breo ElliptaFluticasone/Vilanterol11$6,231
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen298$5,946
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen147$4,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$793$84,55477 claims
Boehringer IngelheimJardiance$238$59,12138 claims
PfizerEliquis, Premarin, Paxlovid$448$58,78590 claims
Novo NordiskOzempic$1,661$43,74433 claims
GSKTrelegy Ellipta, Breo Ellipta$505$33,34335 claims
AbbVieVraylar, Linzess, Synthroid$809$32,14266 claims
Otsuka America Pharmaceutical, Inc.Rexulti$163$16,51212 claims
Astellas Pharma US IncMyrbetriq$33$15,82914 claims
Sumitomo Pharma America, Inc.Gemtesa$53$10,88713 claims
AstraZenecaSymbicort$707$10,40022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →